Hallow, K. Melissa

Why do SGLT2 inhibitors reduce heart failure hospitalization? Adifferential volume regulation hypothesis

Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 499

Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis

Hallow, K. M., Gebremichael, Y., Helmlinger, G., & Vallon, V. (2017) · American Journal of Physiology-Renal Physiology

Chronic Kidney Disease and DiabetesIon Transport and Channel Regulation

Cited by 98

Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data

Hallow, K. M., Greasley, P. J., Helmlinger, G., Chu, L., Heerspink, H. J., & Boulton, D. W. (2018) · American Journal of Physiology-Renal Physiology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 68

A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model

Hallow, K. M., Lo, A., Beh, J., Rodrigo, M., Ermakov, S., Friedman, S., de Leon, H., Sarkar, A., Xiong, Y., Sarangapani, R., et al. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology

Renin-Angiotensin System StudiesBlood Pressure and Hypertension Studies

Cited by 68

Drug-disease modeling in the pharmaceutical industry-where mechanistic systems pharmacology and statistical pharmacometrics meet

Helmlinger, G., Al-Huniti, N., Aksenov, S., Peskov, K., Hallow, K. M., Chu, L., Boulton, D., Eriksson, U., Hamrén, B., Lambert, C., et al. (2017) · European Journal of Pharmaceutical Sciences

Statistical Methods in Clinical TrialsPharmaceutical studies and practices

Cited by 33